Patient and transplant characteristics
| . | Training (n = 352) . | Validation (n = 378) . | P value . |
|---|---|---|---|
| Median Age, yr (range) | 53 (0-75) | 53.5 (0-74) | .520 |
| Age (yr), n (%) | .003 | ||
| <18 | 39 (11.1) | 56 (14.8) | — |
| 18-60 | 235 (66.8) | 206 (54.5) | — |
| >60 | 78 (22.1) | 116 (30.7) | — |
| Indication for HCT, n (%) | <.001 | ||
| Acute leukemia | 192 (54.5) | 196 (51.9) | — |
| MDS/MPS | 69 (19.6) | 111 (29.4) | — |
| Lymphoma | 44 (12.6) | 32 (8.5) | — |
| Nonmalignant | 12 (3.4) | 21 (5.5) | — |
| Other malignant | 35 (9.9) | 18 (4.7) | — |
| Conditioning intensity, n (%) | .003 | ||
| Myeloablative | 245 (69.6) | 222 (58.7) | — |
| Reduced intensity/nonmyeloablative | 107 (30.4) | 156 (41.3) | — |
| Donor type, n (%) | <.001 | ||
| Related | 99 (28.1) | 95 (25.1) | — |
| Unrelated | 245 (69.6) | 246 (65.1) | — |
| Haploidentical | 8 (2.3) | 37 (9.8) | — |
| HLA match, n (%) | <.001 | ||
| Matched | 257 (73.0) | 271 (71.7) | — |
| Mismatched | 87 (24.7) | 70 (18.5) | — |
| Haploidentical | 8 (2.3) | 37 (9.8) | — |
| GVHD serotherapy, n (%) | <.001 | ||
| ATG | 102 (29.0) | 159 (42.1) | — |
| No ATG | 250 (71.0) | 219 (57.9) | — |
| GVHD prophylaxis, n (%) | <.001 | ||
| CNI/MTX ± other | 204 (57.9) | 206 (54.5) | — |
| CNI/MMF ± other | 127 (36.1) | 87 (23.0) | — |
| Tacrolimus + sirolimus | 1 (0.3) | 10 (2.6) | — |
| Cyclophosphamide based | 17 (4.8) | 56 (14.8) | — |
| T-cell depletion | 1 (0.3) | 15 (4.0) | — |
| Other | 2 (0.6) | 4 (1.1) | — |
| Stem cell source, n (%) | .256 | ||
| Marrow | 52 (14.8) | 67 (17.7) | — |
| Peripheral blood | 267 (75.8) | 286 (75.7) | — |
| Cord | 33 (9.4) | 25 (6.6) | — |
| Diagnosis GVHD: median day (range) | 26 (7-273) | 28 (5-196) | <.001 |
| Late-onset GVHD, n (%) | 9 (2.6) | 35 (9.3) | <.001 |
| Diagnosis GVHD grade, n (%) | .920 | ||
| Grade I* | 150 (42.6) | 162 (42.8) | — |
| Grade II | 138 (39.2) | 147 (38.9) | — |
| Grade III | 54 (15.4) | 55 (14.6) | — |
| Grade IV | 10 (2.8) | 14 (3.7) | — |
| Minnesota risk at Dx, n (%) | .611 | ||
| Standard | 296 (84.1) | 324 (85.7) | — |
| High | 56 (15.9) | 54 (14.3) | — |
| Target organ involvement at Dx, n (%) | .285 | ||
| Skin only | 198 (56.3) | 202 (53.4) | — |
| Liver only | 2 (0.6) | 4 (1.1) | — |
| UGI only | 23 (6.5) | 36 (9.5) | — |
| LGI ± other target organ | 113 (32.1) | 110 (29.1) | — |
| Other combinations | 16 (4.5) | 26 (6.9) | — |
| Maximum GVHD Grade II-IV, n (%) | 277 (78.7) | 277 (73.3) | .105 |
| Maximum GVHD Grade III-IV, n (%) | 135 (38.4) | 117 (31) | .043 |
| 6-month NRM (%) | 20.2 | 13.8 | .021 |
| Maximum GVHD grade, n (%) | .138 | ||
| Grade I* | 75 (21.3) | 102 (27.0) | — |
| Grade II | 142 (40.4) | 159 (42.1) | — |
| Grade III | 73 (20.7) | 65 (17.2) | — |
| Grade IV | 62 (17.6) | 52 (13.8) | — |
| Treated with systemic corticosteroids, n (%) | 311 (88.4) | 323 (85.4) | .293 |
| . | Training (n = 352) . | Validation (n = 378) . | P value . |
|---|---|---|---|
| Median Age, yr (range) | 53 (0-75) | 53.5 (0-74) | .520 |
| Age (yr), n (%) | .003 | ||
| <18 | 39 (11.1) | 56 (14.8) | — |
| 18-60 | 235 (66.8) | 206 (54.5) | — |
| >60 | 78 (22.1) | 116 (30.7) | — |
| Indication for HCT, n (%) | <.001 | ||
| Acute leukemia | 192 (54.5) | 196 (51.9) | — |
| MDS/MPS | 69 (19.6) | 111 (29.4) | — |
| Lymphoma | 44 (12.6) | 32 (8.5) | — |
| Nonmalignant | 12 (3.4) | 21 (5.5) | — |
| Other malignant | 35 (9.9) | 18 (4.7) | — |
| Conditioning intensity, n (%) | .003 | ||
| Myeloablative | 245 (69.6) | 222 (58.7) | — |
| Reduced intensity/nonmyeloablative | 107 (30.4) | 156 (41.3) | — |
| Donor type, n (%) | <.001 | ||
| Related | 99 (28.1) | 95 (25.1) | — |
| Unrelated | 245 (69.6) | 246 (65.1) | — |
| Haploidentical | 8 (2.3) | 37 (9.8) | — |
| HLA match, n (%) | <.001 | ||
| Matched | 257 (73.0) | 271 (71.7) | — |
| Mismatched | 87 (24.7) | 70 (18.5) | — |
| Haploidentical | 8 (2.3) | 37 (9.8) | — |
| GVHD serotherapy, n (%) | <.001 | ||
| ATG | 102 (29.0) | 159 (42.1) | — |
| No ATG | 250 (71.0) | 219 (57.9) | — |
| GVHD prophylaxis, n (%) | <.001 | ||
| CNI/MTX ± other | 204 (57.9) | 206 (54.5) | — |
| CNI/MMF ± other | 127 (36.1) | 87 (23.0) | — |
| Tacrolimus + sirolimus | 1 (0.3) | 10 (2.6) | — |
| Cyclophosphamide based | 17 (4.8) | 56 (14.8) | — |
| T-cell depletion | 1 (0.3) | 15 (4.0) | — |
| Other | 2 (0.6) | 4 (1.1) | — |
| Stem cell source, n (%) | .256 | ||
| Marrow | 52 (14.8) | 67 (17.7) | — |
| Peripheral blood | 267 (75.8) | 286 (75.7) | — |
| Cord | 33 (9.4) | 25 (6.6) | — |
| Diagnosis GVHD: median day (range) | 26 (7-273) | 28 (5-196) | <.001 |
| Late-onset GVHD, n (%) | 9 (2.6) | 35 (9.3) | <.001 |
| Diagnosis GVHD grade, n (%) | .920 | ||
| Grade I* | 150 (42.6) | 162 (42.8) | — |
| Grade II | 138 (39.2) | 147 (38.9) | — |
| Grade III | 54 (15.4) | 55 (14.6) | — |
| Grade IV | 10 (2.8) | 14 (3.7) | — |
| Minnesota risk at Dx, n (%) | .611 | ||
| Standard | 296 (84.1) | 324 (85.7) | — |
| High | 56 (15.9) | 54 (14.3) | — |
| Target organ involvement at Dx, n (%) | .285 | ||
| Skin only | 198 (56.3) | 202 (53.4) | — |
| Liver only | 2 (0.6) | 4 (1.1) | — |
| UGI only | 23 (6.5) | 36 (9.5) | — |
| LGI ± other target organ | 113 (32.1) | 110 (29.1) | — |
| Other combinations | 16 (4.5) | 26 (6.9) | — |
| Maximum GVHD Grade II-IV, n (%) | 277 (78.7) | 277 (73.3) | .105 |
| Maximum GVHD Grade III-IV, n (%) | 135 (38.4) | 117 (31) | .043 |
| 6-month NRM (%) | 20.2 | 13.8 | .021 |
| Maximum GVHD grade, n (%) | .138 | ||
| Grade I* | 75 (21.3) | 102 (27.0) | — |
| Grade II | 142 (40.4) | 159 (42.1) | — |
| Grade III | 73 (20.7) | 65 (17.2) | — |
| Grade IV | 62 (17.6) | 52 (13.8) | — |
| Treated with systemic corticosteroids, n (%) | 311 (88.4) | 323 (85.4) | .293 |
ATG, anti-thymocyte globulin; CNI, calcineurin inhibitor; Dx, diagnosis; LGI, lower GI; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MPS, myeloproliferative syndrome; MTX, methotrexate; UGI, upper GI.
Includes 1 patient with biopsy-proven liver GVHD and total bilirubin <2 mg/dl.